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all cases but one with EGFR mutation exhibited a hobnail cell type 
dominancy. In the morphological features, hobnail cell type and the 
presence of BAC and MPP component are good predictors of EGFR 
mutations in pulmonary adenocarcinoma.
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Background: Pulmonary NE tumors are a distinct subset of tumors 
composing approximately 20% of all lung cancers. The main tumor 
types include typical carcinoid (TC), atypical carcinoid (AC), large cell 
NE carcinoma (LCNEC) and small cell carcinoma (SCLC). Although 
pulmonary NE tumors share certain morphologic, immunohistochemi-
cal, and ultrastructural features, they represent a broad clinicopatholog-
ic spectrum with varying morphologic features and biological behavior. 
Their clinicopathologic characteristics and relative grade of malignancy 
have not yet been well deﬁned and are still being assessed.
Methods: 317 cases of surgically resected pulmonary NE tumors 
diagnosed between 1992 and 2006 from the surgical pathology records 
of the Department of Pathology at Memorial Sloan-Kettering Cancer 
Center were reassessed retrospectively according to 2004 World Health 
Organization classiﬁcation. A detailed review of the gross and histo-
logic features was performed and the clinical features and followup 
were obtained from medical records. 
Results: Of 317 cases, there were 171 TC (53.9%), 19 AC (6.0%), 79 
LCNEC (24.9%) and 48 SCLC (15.2%). Patients were 133 men and 
184 women with an average age of 63 years. The median tumor size 
was 2.1 cm, ranging from 0.5 to 12.5 cm. LCNEC and SCLC cases 
tended to have larger tumor size (p<0.001) than TC and AC cases. 
Compared with other NE tumors, TC cases affected women signiﬁ-
cantly more often than men (p=0.01). Smoking was more frequent (%) 
and heavier (mean pack years) in LCNEC (98%, 61) and SCLC (97%, 
57) compared to TC (56%, 17) and AC (60%, 14) (p<0.001). The his-
tologic groups showed signiﬁcant correlations with several pathologic 
factors including vascular invasion (p<0.001), lymph node metastasis 
(p<0.001), pleural invasion (p<0.001), and stage (p<0.001). Mean age 
(yrs) for TC (56.7) and AC (58.7) patients was signiﬁcantly less than 
for SCLC (67.6) but not LCNEC (63.5) patients; LCNEC patients were 
signiﬁcantly younger than SCLC patients (p=0.008). 5-year survival 
rates for patients with all stages were 97.7% for TC, 78.9% for AC, 
51.9% for LCNEC and 37.5% for SCLC (p<0.001). Survival was 
signiﬁcantly better for TC compared to AC (p=0.002), better for AC 
compared to LCNEC (p=0.01) and SCLC (p=0.002) but there was no 
signiﬁcant difference in survival between LCNEC and SCLC (p=0.253) 
(Fig. 1). 
Conclusions: Our data conﬁrms that TC are low grade, AC intermedi-
ate grade and that LCNEC and SCLC are high grade NE lung tumors. 
We also found SCLC patients are signiﬁcantly older than LCNEC as 
well as both TC and AC patients. Smoking was more frequent and 
heavier in high grade NE tumor patients compared to both TC and 
AC patients. Further clinical and molecular studies may advance 
understanding of the optimal treatment and molecular biology of these 
tumors, especially in AC and LCNEC.
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Introduction: Primary rhabdoid tumor of lung is a rare histologi-
cal and clinical entity. Lung tumors with rhabdoid features have been 
included as a variant of large cell carcinoma in 1999 WHO classiﬁca-
tion of lung tumors. Primary lung rhabdoid is very rare with only 39 
cases reported till date and therefore clinical and radiological data are 
required to establish the diagnosis and exclude an asymptomatic renal 
primary We describe our experience with treating a case of rhabdoid 
tumor of lung with an aim to add to the existing body of literature about 
this rare histology.
Materials and Methods: A 36 year old lady presented to us in March 
2003 with a history of hemoptysis about 3-4 times. There was no histo-
ry of cough, expectoration, fever, chest pain or dyspnea. CT scan chest 
showed left lung upper lobe mass 5*5 cm abutting mediastinal vascular 
structures. Bronchial biopsy was strongly suspicious of malignancy 
Metastatic workup was normal. She underwent left pneumonectomy 
in May 2003. Post-op gross pathology report showed a 6*5 cm tumor. 
Microscopic examination revealed markedly cellular tumor, arranged 
in lobules and separated by ﬁbrocollagenous septae. Tumor cells were 
oval to polygonal in shape with abundant cytoplasm, vesicular nucleus, 
some of them having prominent nucleolus. Immunohistochemical stain-
ing showed positivity to S-100, Vimentin, and EMA. It was negative 
for LCA, HMB-45 and CEA. A diagnosis of undifferentiated carci-
noma, Rhabdoid Variant was made. Resected margins of bronchus and 
lymph nodes were free of tumor. She received adjuvant chemotherapy 
with inj. Paclitaxel(175mg/m2) i.v. D1, inj. Carboplatin AUC5 i.v. D2, 
4weekly for 6 cycles from august 2003 to January 2004. Follow up CT 
scan in November 2005 revealed liver metastases in segments 2 & 3 
with no disease in the chest. FNAC from the liver lesion showed metas-
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tic undifferentiated carcinoma. She underwent left lateral hepatectomy 
in January 2006. Histopathology conﬁrmed metastatic rhabdoid tumor 
with negative margins of resection. She received further chemotherapy 
with six cycles of injection Docetaxel (75mg/m2) i.v. D1 3 weekly from 
February 2006 to June 2006. 
Result: Follow up PET scan in July 2006 showed no evidence of 
disease. A repeat PET scan in February 2007 showed a sustained remis-
sion. 
Conclusion: The present case shows that with aggressive management, 
long term remission can be achieved in rhabdoid tumor of lung. 
IHC marker
Cavazza 
et al 
Tamboli 
et al 
Shimakazi 
et al 
Miyagi 
et al 
TOTAL
percent-
age
Cytokeratin 3/6 9/11 12/14 3/3 27/34 79.4
Epithelial membrane 
antigen 5/6 X 6/14 3/3 14/23 60.8
Vimentin 6/6 11/11 14/14 3/3 34/34 100
S-100 0/6 X X 0/3 0/9  
HMB-45 0/6 X 0/14 X 0/20  
CAM 5.2 2/6 X X X 2/6 33.3
Glial Fibrillary acidic 
Protein 1/6 X 0/14 X 1/20 5
Chromogranin 2/6 X 2/14 3/3 7/23 30.4
Neuroﬁlaments 2/6 X 1/14 X 3/20 15
Neuron Speciﬁc 
Enolase 5/6 X 5/14 2/3 12/23 52
Factor VIII 0/6 X X X 0/6  
CD 34 1/6 X 1/14 X 2/20 10
Muscle Speciﬁc Actin 0/6 X X X 0/6  
Desmin 0/6 X 0/14 0/3 0/20  
Myoglobin 1/6 X 0/14 0/3 1/20 5
Cytokeratin 7 X 4/11 X X 4/11 36.3
Cytokeratin 20 X 0/11 X X 0/11  
Thyroid Transcription 
Factor-1 X 0/11 X X 0/11  
Synaptophysin X X 1/14 2/3 3/17 17
CD 57 X X 0/14 X 0/14  
c-kit X X 0/14 X 0/14  
HHF-35 X X 0/14 0/3 0/17  
Surfactant  
Apoprotein A X X X 1/3 1/3 33.3
CD56 X X X 1/3 1/3 33.3
GM-CSF X X X 1/3 1/3 33.3
G-CSF X X X 1/3 1/3 33.3
p53 X X X 0/3 0/3  
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Introduction: Bronchioloalveolar Lung Carcinoma (BALC) has long 
been an entity with particular characteristics, discussed over several 
decades. Its diagnosis, treatment and prognosis differ somewhat from 
other histological types of lung carcinoma. In 2003, the World Health 
Organization redeﬁned the pathologic characteristics of the BALC. Ac-
cording to these, only histological data allow its diagnosis.
Objectives: The authors aim to observe and discuss the repercussions 
of the new classiﬁcation criteria for BALC on its prognosis and associ-
ated survival, in patients submitted to lung surgery.
Material and Methods: Retrospective analysis of 18 patients submit-
ted to either diagnostic or curative surgery for lung carcinoma between 
years 2001 and 2005, diagnosed with BALC. Initial histological 
diagnoses were revised according to the recently adopted criteria for 
BALC, leading to the distinction of two separate groups: “pure” BALC 
and Mixed adenocarcinoma. Analysis of lesion size, TNM staging, 
need for chemo- (QT) or radio- (RT) adjuvant therapy as well as mean 
survival were compared among these 2 groups.
Results: 
Histological Type BALC Mixed Total
Total number of patients 7 11 18
Number of male patients 2 7 9
Mean age (years) 60.1 58.5 59.1
Mean Mass diameter (cm) 3.04 4.47 3.84
Mean survival (months) 38.1 28.6 32.3
1-year survival rate (%) 100 63.6 77.8
Fatalities 3 (42.9%) 6 (54.5%) 9 (50%)
Ia 4 2 6
Ib 3 3 6
IIb - 3 3
IIIb - 3 3
QT 1 7 8
RT - 5 5
Discussion: Despite the small sample size, some simple facts stand out: 
• Patient age was slightly lower and mass diameter larger in the mixed 
group;
• There was a greater predominance of advanced TNM stages in the 
“mixed” group, an expected fact taking the deﬁnition of BALC in 
itself into account;
• But one patient in the BALC group was submitted to chemotherapy 
and none to radiotherapy; on the other hand, a great proportion of 
patients in the “mixed” group was submitted to these treatments; 
• The relative number of deaths was slightly larger in the “Mixed” 
group;
• 1-year survival rate was of 100% in the BALC group unlike the 
Mixed group where it was of 63.6%;
